Stay updated on PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Sign up to get notified when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.

Latest updates to the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page
- Check2 days agoChange DetectedThe revision tag on the page was updated from v3.6.3 to v3.6.4, indicating a minor administrative update to the page's revision history. There are no changes to study content or user-facing features.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now displays a new revision tag replacing the previous one, indicating a maintenance update without altering study details or user-facing content.SummaryDifference0.1%

- Check30 days agoChange DetectedThe page’s revision line shows a new version (v3.6.2) replacing the old v3.6.0, indicating an update to the page template. This change applies a newer page version without altering the study information shown.SummaryDifference0.1%

- Check44 days agoChange DetectedThe study record page adds new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and adjusts the Intervention/Treatment heading formatting while introducing a new Revision: v3.6.0 label. This reflects a minor editorial update to the page's structure and labeling without changing trial information.SummaryDifference0.5%

- Check51 days agoChange DetectedThe page now shows revision v3.5.5, replacing the previous v3.5.4, indicating a new content revision.SummaryDifference0.1%

- Check73 days agoChange DetectedThe page's Revision tag was updated from v3.5.3 to v3.5.4, indicating a minor backend/template update rather than any changes to the study details or user-facing information.SummaryDifference0.1%

Stay in the know with updates to PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Enter your email address, and we'll notify you when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.